Monitor for any follow-up from the FDA, as regulatory compliance issues in biotech can escalate. While the immediate risk appears mitigated by the company's response, continued scrutiny could impact investor sentiment or future promotional strategies.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $7.08entry
- T+1 · 7mo ago −3.11%α −3.17% · $6.86
- T+5 · 7mo ago +3.11%α −1.03% · $7.30
- T+20 · 7mo ago +4.94%α −4.04% · $7.43
- T+60 · 5mo ago +29.94%α +16.47% · $9.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.
Key Facts
- FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
- ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
- The company removed the identified podcast from its website and requested removal from third-party platforms.
- Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.
- The statements in question were made during a podcast by Founder Dr. Patrick Soon-Shiong and were described as aspirational and forward-looking.
Financial Impact
No direct financial impact disclosed. No fines, penalties, or material financial adjustments were mentioned.
Risk Factors
- Potential for further FDA action if compliance concerns are not fully resolved.
- Reputational risk from regulatory scrutiny, which could affect physician or patient confidence in the company or its product.
- Risk of future non-compliance if internal controls are not effectively strengthened.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142932 |
| Document: d70606dex991.htm | 0001193125-26-142932 |
| Document: 0001193125-26-142932-index-headers.html | 0001193125-26-142932 |
| Document: 0001193125-26-142932-index.html | 0001193125-26-142932 |
| Document: 0001193125-26-142932.txt | 0001193125-26-142932 |
Track record
11 reports on IBRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Viewing Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers